Osteoarthritis, Knee — Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty
Citation(s)
Aggarwal AK, Singh N, Sudesh P Topical vs Intravenous Tranexamic Acid in Reducing Blood Loss After Bilateral Total Knee Arthroplasty: A Prospective Study. J Arthroplasty. 2015 Dec 21. pii: S0883-5403(15)01114-6. doi:10.1016/j.arth.2015.12.033. [Epub ahead of print]
Benoni G, Lethagen S, Fredin H The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb Res. 1997 Feb 1;85(3):195-206. Erratum in: hromb Res 1997 Oct 15;88(2):251.
Charoencholvanich K, Siriwattanasakul P Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial. Clin Orthop Relat Res. 2011 Oct;469(10):2874-80. doi: 10.1007/s11999-011-1874-2. Epub 2011 Apr 22.
Dunn CJ, Goa KL Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32. Review.
Eubanks JD Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010 Mar;18(3):132-8. Review.
Gonzalez-Porras JR, Colado E, Conde MP, Lopez T, Nieto MJ, Corral M An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med. 2009 Feb;19(1):35-42. doi: 10.1111/j.1365-3148.2009.00908.x.
Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2009 Mar;123(5):687-96. doi: 10.1016/j.thromres.2008.09.015. Epub 2008 Nov 12. Review.
Manor D, Sadeh M Muscle fibre necrosis induced by intramuscular injection of drugs. Br J Exp Pathol. 1989 Aug;70(4):457-62.
Murphy WG, Davies MJ, Eduardo A The haemostatic response to surgery and trauma. Br J Anaesth. 1993 Feb;70(2):205-13. Review.
Orpen NM, Little C, Walker G, Crawfurd EJ Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients. Knee. 2006 Mar;13(2):106-10. Epub 2006 Feb 17.
Parvizi J, Diaz-Ledezma C Total knee replacement with the use of a tourniquet: more pros than cons. Bone Joint J. 2013 Nov;95-B(11 Suppl A):133-4. doi: 10.1302/0301-620X.95B11.32903.
Pinsornsak P, Chumchuen S Can a modified Robert Jones bandage after knee arthroplasty reduce blood loss? A prospective randomized controlled trial. Clin Orthop Relat Res. 2013 May;471(5):1677-81. doi: 10.1007/s11999-013-2786-0. Epub 2013 Jan 11.
Pitta M, Zawadsky M, Verstraete R, Rubinstein A Intravenous administration of tranexamic acid effectively reduces blood loss in primary total knee arthroplasty in a 610-patient consecutive case series. Transfusion. 2016 Feb;56(2):466-71. doi: 10.1111/trf.13354. Epub 2015 Oct 28.
Roy SP, Tanki UF, Dutta A, Jain SK, Nagi ON Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2012 Dec;20(12):2494-501. doi: 10.1007/s00167-012-1942-5. Epub 2012 Mar 15.
Sinclair KC, Clarke HD, Noble BN Blood management in total knee arthroplasty: a comparison of techniques. Orthopedics. 2009 Jan;32(1):19.
Spreng UJ, Dahl V, Hjall A, Fagerland MW, Ræder J High-volume local infiltration analgesia combined with intravenous or local ketorolac+morphine compared with epidural analgesia after total knee arthroplasty. Br J Anaesth. 2010 Nov;105(5):675-82. doi: 10.1093/bja/aeq232. Epub 2010 Aug 24.
Wang H, Shen B, Zeng Y Blood Loss and Transfusion After Topical Tranexamic Acid Administration in Primary Total Knee Arthroplasty. Orthopedics. 2015 Nov;38(11):e1007-16. doi: 10.3928/01477447-20151020-10. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
